Analyst Price Targets — ASMB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 15, 2026 10:57 am | — | Mizuho Securities | $45.00 | $22.96 | TheFly | Assembly Biosciences price target raised to $45 from $40 at Mizuho |
| November 20, 2025 12:09 pm | Salim Syed | Mizuho Securities | $40.00 | $39.00 | TheFly | Assembly Biosciences price target raised to $40 from $29 at Mizuho |
| September 24, 2025 8:29 am | Roy Buchanan | JMP Securities | $38.00 | $25.90 | TheFly | Assembly Biosciences initiated with an Outperform at Citizens JMP |
| September 24, 2024 6:41 am | Salim Syed | Mizuho Securities | $36.00 | $16.26 | StreetInsider | Mizuho Reiterates Outperform Rating on Assembly Biosciences (ASMB) |
| September 20, 2024 3:30 am | Dennis Ding | Jefferies | $35.00 | $18.50 | StreetInsider | Jefferies Upgrades Assembly Biosciences (ASMB) to Buy |
Latest News for ASMB
Assembly Biosciences has evolved into a strategically financed antiviral platform, underpinned by a robust partnership with Gilead and a strengthened balance sheet. ASMB's pipeline targets high-unmet-need indications—recurrent genital herpes, HDV, and cholestatic liver diseases—with differentiated mechanisms and strong early clinical data. Pro forma liquidity exceeds $340 million post-offering, supporting operations…
Assembly Biosciences NASDAQ: ASMB outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions tied to its herpes simplex virus type 2 program, expansion of its hepatitis delta candidate into cholestatic liver diseases and expected clinical data readouts in 2027 and 2028.
Assembly Biosciences, Inc. (ASMB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Assembly Biosciences NASDAQ: ASMB is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event.
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will participate in fireside chats at two upcoming investor conferences:
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ASMB.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.